Drug Profile
Cefpodoxime/ETX 0282 - Entasis Therapeutics
Alternative Names: ETX 0282/Cefpodoxime - Entasis Therapeutics; ETX0282CPDPLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Entasis Therapeutics
- Class Anti-infectives; Antibacterials; Cephalosporins; Heterocyclic bicyclo compounds
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Urinary tract infections
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Urinary-tract-infections(In volunteers, Complicated) in Australia (PO, Capsule)
- 07 May 2021 Cefpodoxime/ETX 0282 is still in phase-I clinical trials in Urinary tract infections in Australia (PO) (Entasis Therapeutic pipeline, May 2021)
- 31 Dec 2020 Entasis Therapuetics has patent protection for durlobactam in USA and other countries